Product Description
Pegbelfermin (BMS-986036), a PEGylated human fibroblast growth factor 21 (FGF21) analogue, has previously been shown to improve markers of metabolism and liver fibrosis in obese patients with type 2 diabetes. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30554783/)
Mechanisms of Action: FGF21 Agonist
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additional Commercial Interests: Ambrx
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Fatty Liver, Alcoholic|Type 2 Diabetes|Liver Cirrhosis|Non-alcoholic Steatohepatitis|Liver Cirrhosis, Alcoholic|Hepatitis, Alcoholic|Liver Diseases, Alcoholic
Phase 1: Hepatitis, Alcoholic|Liver Cirrhosis, Alcoholic|Non-alcoholic Steatohepatitis|Healthy Volunteers|Fatty Liver, Alcoholic|Liver Diseases, Alcoholic|Overweight
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MB130-112 | P1 |
Completed |
Hepatitis, Alcoholic|Liver Cirrhosis, Alcoholic|Non-alcoholic Steatohepatitis |
2022-06-02 |
21% |
| JapicCTI-184033 | P2 |
Unknown |
Liver Cirrhosis|Non-alcoholic Steatohepatitis|Fatty Liver, Alcoholic|Hepatitis, Alcoholic |
2021-11-05 |
|
| MB130-063 | P1 |
Withdrawn |
Overweight |
2021-09-21 |
22% |
| MB130-101 | P1 |
Completed |
Overweight |
2021-06-11 |
22% |